Project Details
Description
MT2024-41: A Phase I Study of FT536 in Combination with Isatuximab in Patients with Relapsed or Refractory Myeloid Neoplasms and Multiple Myeloma.
| Status | Finished |
|---|---|
| Effective start/end date | 8/28/25 → 11/26/25 |
Funding
- CHILDREN'S CANCER RESEARCH FUND
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.